- 1 Community benefits of mass distribution of three types of dual-active-ingredient long-lasting
- 2 insecticidal nets against malaria prevalence in Tanzania: evidence from a 3-year cluster-
- 3 randomized controlled trial

Eliud Andrea Lukole<sup>1,2\*</sup> Jackie Cook<sup>3</sup>, Jacklin F Mosha<sup>1,</sup>, Nancy S Matowo<sup>2</sup>, Manisha A Kulkarni<sup>4</sup> 4 Elizabeth Mallya<sup>5</sup>, Tatu Aziz<sup>1</sup>, Jacklin Martin<sup>5</sup> Mark Rowland<sup>2</sup>, Immo Kleinschmidt<sup>3,9,10</sup>, Alphaxard 5 6 Manjurano<sup>1</sup>, Safari Kinung'hi<sup>1</sup>, Franklin W Mosha<sup>5</sup>, Natacha Protopopoff<sup>2</sup> 7 1. Department of Parasitology, National Institute for Medical Research, Mwanza Medical 8 9 Research Centre, Mwanza, Tanzania 2. Department of Disease Control, London School of Hygiene and Tropical Medicine, London, 10 United Kingdom 11 12 3. MRC International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United 13 Kingdom 14 4. School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada 15 16 5. Kilimanjaro Christian Medical University College, Moshi, Tanzania 6. National Malaria Control Program, Ministry of Health, Community Development, Gender, 17 Elderly and Children, Dar es Salaam, Tanzania 18 19 7. Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa 20 8. Southern African Development Community Malaria Elimination Eight Secretariat, 21 22 Windhoek, Namibia 23 Abstract 24

#### Background 25

- Long-lasting insecticidal nets (LLINs) were once fully effective for the prevention of malaria; 26
- however, mosquitoes have developed resistance to pyrethroids, the main class of insecticides used 27
- on nets. Dual active ingredient LLINs (dual-AI LLINs) have been rolled out as an alternative to 28
- pyrethroid (PY)-only LLINs to counteract this. Understanding the minimum community usage at 29
- 30 which these novel nets generate an effect that also benefits non-net users against malaria infection is
- vital for planning net distribution strategies and mobilization campaigns. 31

#### Methods 32

- 33 We conducted a secondary analysis of a 3-year randomized controlled trial (RCT) in 84 clusters in
- North-western Tanzania to evaluate the effectiveness of three dual-AI LLINs: pyriproxyfen and 34
- alpha( $\alpha$ )-cypermethrin (pyriproxyfen-PY), chlorfenapyr and  $\alpha$ -cypermethrin (chlorfenapyr-PY), and 35
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. the synergist piperonyl-butoxide and permethrin (PBO-PY) compared to  $\alpha$ -cypermethrin only nets 36

(PY-only). We measured malaria infection prevalence using 5 cross-sectional surveys between 2020
and 2022. We assessed net usage at the cluster level and malaria infection in up to two children aged
between 6 months and 14 years in 45 households per cluster and compared infection prevalence
between net users and non-users with the different net types and usage levels.

41 Findings

A total of 22,479 children from 12,654 households were tested for malaria using rapid diagnostic 42 tests in January 2020, 2021, & 2022 and July 2020 & 2021. In all surveys combined, 23% 43 (5,062/22,479) of children reported not using a net the night before the surveys. The proportion of 44 non-net users was highest in the later surveys. Across all study arms and at each time point, users of 45 nets had significantly lower malaria infection than non-users. Overall, malaria prevalence was 52% 46 (2649/5062) among non-net users and 32% (5572/11845) among users (of any net). Among non-net 47 users, community-level usage of >40% of dual-AI LLIN was significantly associated with protection 48 against malaria infection: chlorfenapyr-PY (OR: 0.44 (95% CI: 0.27-0.71), p=0.0009), PBO-PY (OR: 49 0.55 (95% CI: 0.33-0.94), p=0.0277) and pyriproxyfen-PY (OR: 0.61 (95% CI: 0.37-0.99), p=0.0470) 50 compared with non-users in clusters with >40% usage of PY-only LLINs. There was weak evidence 51 52 of protection against malaria infection to non-net users in the chlorfenapyr-PY arm when community-53 level usage was  $\leq 40\%$  (OR: 0.65 (95% CI: 0.42-1.01), p=0.0528) compared to those living in clusters with >40% usage of pyrethroid-only LLINs. The study was limited to non-users which were defined 54 as participants who did not sleep under any net the night before. This might not capture occasional 55 net usage during the week. 56

### 57 Conclusion

Our study demonstrated that at a community usage of 40% or more of dual-AI LLINs, non-net users benefited from the presence of these nets. Noticeably, even when usage was ≤40% in the chlorfenapyr-PY arm, non-users were better protected than non-users in the higher coverage PY-only arm. The greater difference in malaria risk observed between users and non-users across all study arms indicates that nets play a crucial role in providing personal protection against malaria infection

for the people using the net and that net usage needs to be maximized to realize the full potential ofall nets.

65

### 66 Funding

Department for International Development, UK Medical Research Council, Wellcome Trust, and
Department of Health and Social Care (#MR/R006040/1). The Bill and Melinda Gates Foundation
via the Innovative Vector Control Consortium (IVCC).

70 Keywords: dual active ingredient LLINs, community effect, malaria prevalence, Tanzania

## 71 Background

Long-lasting insecticidal nets (LLINs) have been the core intervention for malaria control for many 72 years and have contributed to a decline of >25% global cases and >66% global deaths since 2000.1-4 73 LLINs work by providing a barrier preventing mosquitoes from taking bloodmeals from people 74 sleeping under them and by killing or reducing a mosquito's lifespan via the insecticide on the netting, 75 known as a 'community effect'. Only older mosquitoes transmit malaria due to the time required for 76 the parasite to develop in the mosquito between blood meals therefore, reducing the lifespan of 77 mosquitoes ensures fewer can transmit.<sup>5</sup> In this way, LLINs not only reduce vector-human contact 78 for those using the nets but also reduce mosquito vector populations and hence the risk of malaria 79 transmission for the community at large (whether using nets or not).<sup>6-9</sup> This has been demonstrated 80 in experimental hut trials, <sup>10-12</sup> modeling<sup>7, 13</sup>, and community trials <sup>6, 14</sup> where a higher level of 81 coverage of pyrethroid-only nets resulted in a decrease in malaria risk, even in those not using nets. 82 Previous findings with pyrethroid-only nets have suggested that community coverage needs to be at 83 least 15% and up to 85% before the community effect is realised.<sup>15</sup> However, this is a wide range to 84 rely on for program implementation. 85

The community-wide effect depends on the insecticidal properties of the LLIN,<sup>16</sup> as well as LLIN characteristics (coverage, netting integrity), and vector species behaviour (anthropophilic and

zoophilic nature).<sup>17</sup> Moreover, the presence of non-human alternative hosts, time spent indoors, under
a net, and outdoors during peak biting hours, and insecticide resistance are also determinants of mass
effect.

Insecticide resistance continues to be a threat to the effectiveness of pyrethroid-only LLINs.<sup>10, 16, 18-23</sup> In high insecticide resistance settings, the main mechanism of protection to pyrethroid-only net users is likely to be via the physical barrier of the net preventing mosquito bites- meaning non-users do not benefit to the same extent. Therefore, switching to novel malaria control tools, such as dual-AI LLINs is imperative.<sup>22</sup>

96 Dual-AI LLINs have been shown to be more effective than pyrethroid-only nets, where mosquitoes 97 are resistant to pyrethroids.<sup>24-29</sup> This is due to their unique modes of action, ranging from neutralising 98 the potency of pyrethroids in resistant vectors (piperonyl butoxide), sterilizing vectors that survive 99 exposure to pyrethroids (pyriproxyfen), to disrupting the vectors' ability to produce energy 100 (chlorfenapyr), thereby restoring the effectiveness of LLINs against resistant mosquitoes.<sup>24-29</sup> 101 Therefore, understanding the coverage levels required for community-wide effect is vital to help 102 determine net coverage targets and plans for future campaigns.

Tanzania has one of the highest burdens of malaria cases and deaths.<sup>4</sup> In Tanzania, malaria is highest 103 in the Lake Victoria zone. The core malaria intervention in the country is LLINs, which have been 104 distributed widely in the country since 2007.<sup>30</sup> Although Tanzania has made great efforts to 105 implement LLINs in the general population, gaps in use, access, coverage, and ownership remain. As 106 such, several distribution channels including mass campaigns, School Net Programs (SNP), antenatal 107 care (ANC) and the Expanded Programme on Immunization and Targeted Replacement Campaign 108 109 (TRC) are being implemented across the country. Dual-AI LLINs, particularly PBO LLINs, have been distributed in Tanzania through the SNP and ANC since 2018 in areas with high malaria burden, 110 however, high coverage of the population at risk remains a challenge. An understanding of the 111

required level of coverage to achieve community benefits is key to the proper allocation of limitedmalaria control resources.

In this study, we assess malaria risk among users and non-users living in areas with different community coverage of dual-AI LLINs as part of a secondary analysis of a large RCT assessing the impact of dual-AI LLIN in Misungwi, Tanzania.<sup>26</sup>

117

118 Methods

# 119 Study site, design, and participants

Data used for this secondary analysis was collected in a 3-year, four parallel-arm cluster randomized 120 controlled trial (cRCT) conducted in 84 clusters on the southern border of Lake Victoria, Misungwi 121 district (latitude 2°51'00.0"S, longitude 33°04'60.0" E), Mwanza region, in North-western 122 Tanzania.<sup>26, 31</sup> The following treatments were randomly allocated to 21 clusters each: Interceptor® 123 with only pyrethroid (PY) insecticide (alpha-cypermethrin, [control] arm), Interceptor® G2 124 (Chlorfenapyr-PY LLIN (alpha-cypermethrin + chlorfenapyr), Royal Guard® (Pyriproxyfen-PY 125 LLIN (alpha-cypermethrin + pyriproxyfen), and Olyset<sup>TM</sup> Plus (permethrin + piperonyl-butoxide 126 (PBO)). The trial is registered with ClinicalTrials.gov (NCT03554616). 127

128

# 129 **Procedures**

A total of 147,230 study LLINs were distributed (1 net for 2 persons) in 42,394 households as part of the trial between January 26 and January 28, 2019. In addition, there was continuous distribution of pyrethroid-only LLINs in the study area through ANC, and in September 2021 (33 months posttrial net distribution), 40,000 PBO LLINs were evenly distributed across study arms via SNP.

134 Malaria infection prevalence was measured during cross-sectional surveys at 12 months (t12;

135 January/February 2020), 18 months (t18; July/August 2020), 24 months (t24; January/February

136 2021), 30 months (t30; July/August 2021), and 36 months (t36; January/February 2022) post-

intervention. Up to two children aged between 6 months and 14 years from 45 randomly selected
households per cluster were tested for malaria infection using rapid diagnostic tests (RDT) (CareStart
malaria HRP2 [pf], DiaSys, Wokingham, UK). In all consenting households, information on residents
was recorded and all nets were visually examined by a trained interviewer, and the information on
use status was recorded.

Data collection took place on smartphones using the Open-Data-Kit (ODK) software. Data from each
field team was directly uploaded to a secure database at the London School of Hygiene and Tropical
Medicine (LSHTM). After completion of the surveys, datasets were transferred to STATA release
15 (StataCorp, College Station, TX, USA) for further aggregation, cleaning, and analysis.

146 Statistical analysis

Household socio-economic status (SES) indices were constructed based on self-reported ownership 147 of certain goods (animals, poultry, phone, radio, bicycle, motorbike) and household possessions 148 (including electricity, source of drinking water, toilet, number of sleeping rooms, type of cooking 149 150 fuel). Principal component analysis (PCA) was used to develop a score which was then subdivided into wealth tertiles (lowest, middle, and highest) at the household level. House characteristics and 151 structures (including roof, floor, eaves, walls, ceiling, and plastering,) were not included in the 152 construction of SES, instead, they were used to create a household design index and subdivided into 153 tertiles (low-quality, medium-quality, and high quality). 154

155

Community LLIN usage was derived as the proportion of all individuals (children and adults) in the household sleeping under study LLINs the previous night in that cluster. To assess the community effect of the dual-AI LLINs (Chlorfenapyr-PY, Pyriproxyfen-PY, and PBO-PY) relative to PY-only LLIN, the following analysis was conducted: 1/ the comparison of malaria prevalence between net users and non-users per arm per timepoint, 2/ comparison of malaria prevalence in non-net users in each dual-A.I. LLIN arm *vs* non-net users in the PY-only LLIN arm, 3/ comparison of malaria prevalence in net users (of any net) in each dual-AI LLIN arm *vs* net users in PY-only LLIN arm.

Analyses 1 to 3 were done regardless of the cluster net usage level. 4/ To check if the level of dual-163 AI LLIN community usage had an impact on the non-net users, we compared malaria prevalence in 164 all participants and non-net users living in clusters with >40% or  $\leq$  40% community usage of dual-165 166 AI LLIN only versus non-users living in standard LLIN (PY-only) clusters with community usage > 40%. Previous studies have demonstrated a strong association between >50% community usage of 167 pyrethroid-only LLINs<sup>7, 32</sup> and decreased malaria, so a lower cut-off (40%) was selected to assess 168 dual-AI LLINs. All analyses used mixed-effect logistic regression assessing the effect of net types 169 and varied usage levels on malaria infection controlling for age, sex, quality of dwelling, and cluster 170 baseline characteristics (malaria infection prevalence in children aged 6 months to 14 years and LLIN 171 usage), with cluster and survey timepoint as random effects. The interaction term between the 172 community-level usage variable and survey timepoint was included to test for the presence of effect 173 modification of the odds ratio. 174

175

## 176 Ethical considerations

Ethical approval for the RCT was obtained from the institutional review boards of the Tanzanian
National Institute for Medical Research (reference number: NIMR/HQ/R.8a/Vol.IX/2743),
Kilimanjaro Christian Medical University College (2267), London School of Hygiene and Tropical
Medicine (14952), and University of Ottawa (H-05-19-4411).

181

# 182 Role of the funding source

183 The funder of the study had no role in study design, data collection, data analysis, data interpretation,184 or writing of the report.

185

### 186 **Results**

Between 07 January 2020 and 10 February 2022, five repeated cross-sectional surveys were
conducted in 12,654 consenting households post-net distribution. Overall, 23% (5062/22479) (14%)

(619/4380) at t12, 22% (1049/4785) at t18, 20% (998/4988) at t24, 30% (1202/3997) at t30, and 28%
(1194/4329) at t36) of children did not sleep under any net the previous night. Residents not sleeping
under study LLINs the previous night doubled in each arm at t36 compared to t12 (Figure 1). Net use
was highest in children under 5 years old. In houses with not enough nets for every member (i.e. less
than 1 net for every 2 people), boys over the age of 5 years were least likely to sleep under a net.
People classified as highest SES were least likely to use nets. However, there was no difference in
usage between girls and boys when under 5 years of age (Table 1).

Following net distribution, malaria prevalence was 52% (2649/5062) in non-net users [34% (210/619) at t12, 58% (612/1049) at t18, 52% (518/998) at t24, 63% (755/1202) at t30, and 46% (554/1194) at t36]; and 32% (5572/11845) in net users overall [20% (754/3761) at t12, 43% (1622/3736) at t18, 34% (1341/3990) at t24, 39% (1102/2795) at t30, 24% (752/3135) at t36]. A summary of malaria prevalence among users of study nets, users of other nets, and non-net users by study arm and survey is presented in (Appendix 1).

202 In non-net users, at t12, there was no evidence for lower malaria prevalence in the dual AI-LLIN arms compared to the PY-only arm. At t18, t24, and t30 no statistically significant reduction in 203 malaria prevalence was observed in either the PBO-PY arm or pyriproxyfen-PY arm compared with 204 205 standard-PY. In non-net users living in the chlorfenapyr-PY arm, the odds of malaria infection were over 40% lower than for non-net users living in the PY-only arm at t18 [t18: adjusted odds ratio 206 (aOR) 0.56 (95% CI 0.35-0.90), p=0.0166], and t30 [aOR 0.57 (95% CI 0.33-0.96), p=0.0353] (Table 207 2). At t36, non-net users in every dual-AI LLIN arm had lower malaria prevalence than non-net users 208 living in the PY-only LLIN arm (Table 2). 209

Across all timepoints, users of nets in the chlorfenapyr-PY arm had reduced odds of malaria infection compared to users of PY-only LLIN. For those using PBO-PY nets, there were reduced odds of malaria infection at t12 and t18 but not at t30 or t36 when compared to net users in the PY-only arm. For those using pyriproxyfen-PY nets, there were reduced odds of infection at t12 and t30 but not at

t18, t24, or t36, compared to those using PY-only nets (Table 2). Within each arm, malaria prevalence 214 was generally significantly lower in net users than in non-net users except at t12 in standard-PY [30%] 215 (286/964)-users vs 41% (64/156)-non-users; p=0.1444] and PBO-PY LLIN [18% (168/941)-users vs 216 217 30% (38/127)-non-users; p=0.0769] (Table 2). Malaria prevalence in non-net users in all three dual-AI arms were similar or higher than amongst net users in the PY-only arm, i.e. the personal protection 218 provided by users of PY-LLIN only nets was similar or slightly better than the protection provided 219 by the community effect of dual-AI nets, however not statistically significant at any time point 220 (Appendix 4). 221

222 Table 3 presents the results of the impact of community usage on community effect by assessing malaria prevalence in non-net-users. Among non-net users, community usage of dual-AI LLIN higher 223 than 40% was associated with reduced odds of malaria infection in those living in the pyriproxyfen-224 PY LLIN arm (aOR: 0.61 [95% CI: 0.37-0.99], p=0.0470), PBO-PY LLIN arm (aOR 0.55 [95% CI: 225 0.33-0.94], p=0.0277); and chlorfenapyr-PY LLIN arm (aOR 0.44 [95% CI: 0.27-0.71], p=0.0009) 226 compared with their counterparts with over 40% usage in the PY-only arm. There was weak evidence 227 of reduced odds of malaria infection in non-users living in the chlorfenapyr-PY LLIN arm when 228 229 community-level usage was  $\leq 40\%$  (55.1% (157/285)) compared to those living in PY-only arms when community usage was over 40% (45.7% (495/1083); aOR 0.65 [95% CI: 0.42-1.01], p= 230 0.0528). 231

High coverage clusters (> 40%) were concentrated in the early years implying that the majority of the nets in this group were new nets (with fresh insecticide), whilst, in the later years, the majority of the clusters were concentrated in  $\leq$ 40% category and hence mostly old nets (Appendix 2). Furthermore, the sensitivity analysis was performed to assess the effect of community coverage levels ( $\leq$  40% and > 40%) on malaria prevalence in all participants (users and non-users on the nets) (Appendix 3).

To see if the effect of community usage was modified by the survey period, we examined for an interaction between usage and survey timepoint. The test for interaction between levels of community dual-AI LLIN usage and survey time point showed no difference in the effect of community dual-AI LLIN usage on the odds of malaria infection among children who did not use nets p=0.3092.

242

### 243 Discussion

This is a secondary analysis of a cluster randomised trial of Dual-Active Ingredient long-lasting 244 insecticidal nets (Dual-AI LLINs) assessing the community effect of three dual-AI LLINs 245 (chlorfenapyr-PY LLIN, pyriproxyfen-PY LLIN, and PBO-PY LLIN) compared with PY-only LLIN. 246 Net users were always more protected than non-net users regardless of net type and survey timepoint, 247 underscoring the importance of personal protection provided by nets. In addition, regardless of 248 community usage levels, non-net users living in the chlorfenapyr-PY arm were more protected than 249 non-net users in the PY-only arm. However, PBO-PY LLIN and pyriproxyfen-PY LLIN did not 250 251 provide better protection to non-net users compared to PY-only LLIN except at 36 months postintervention. We also found that community usage of dual-AI LLIN above 40% provided 252 significantly better protection against malaria infection to non-users compared to the same group in 253 the PY-LLIN arm, and this protection extended to non-users in areas with low ( $\leq 40\%$ ) community 254 usage of chlorfenapyr-PY LLINs. 255

An early review by Lines et al.<sup>15</sup> identified 21 studies assessing the community effect of pyrethroidonly LLINs and reported a wide range of minimum community coverage levels (from 15% to 85%), leading to community effects protecting people sleeping without nets. Consistent with this, a study conducted in Kenya<sup>33</sup> concluded that at least 35% community coverage of nets is required to protect people sleeping without nets, while another study<sup>6</sup> reported that residents not using nets and living within 300 meters from a community using insecticide-treated nets (usage greater than 50%) were protected against malaria compared to those further away. Meanwhile, Lindblade et al.<sup>34</sup> found that

community net usage (>82%) protected both users and non-users equally. Models have been also used to estimate the threshold of community net usage necessary to detect a community effect. For example, Killeen et al.<sup>7</sup> modelled that coverage of 35%-65% would be needed to achieve community-wide benefits. Another model,<sup>23</sup> suggested that as soon as one person uses an LLIN, there is a small indirect impact on non-users (even if marginal at this coverage) compared to a hypothetical scenario where nobody is using an LLIN. The benefits for both users and non-users increase with net usage.

The present study adds to the body of existing evidence and demonstrates that when a net is very 270 271 effective as observed for chlorfenapyr-PY LLINs both users and non-users are protected even at moderate to low levels of community coverage. With less effective nets such as PBO-PY LLIN and 272 pyriproxyfen-PY LLINs, the impact on non-net users was not as important. Users of PBO-PY LLIN 273 had lower malaria prevalence compared to PY-only LLIN users up to 18 months. There was no 274 difference in prevalence between non-users during the same period suggesting limited community 275 protection from these nets except when PBO-PY LLIN community coverage was above 40%. Greater 276 and longer-lasting efficacy has been observed with this class of nets in two other RCTs. Although 277 278 neither of these trials specifically examined the impact of the net on non-users, in Uganda, the effect 279 of PBO-PY LLIN on malaria prevalence was more pronounced when only children using PBO-PY LLIN (per protocol) were considered, rather than including all children regardless of net usage status 280 (intention to treat),<sup>28</sup> suggesting a small or no community effect. The community coverage of PBO-281 282 PY LLIN was not known in this study. In another study in Tanzania, during the first two years of follow-up, similar malaria reduction was observed when intention-to-treat and per-protocol analyses 283 were done, indicating that both non-net users and net users may have been protected equally by PBO-284 PY LLIN.<sup>27</sup> In the third year, however, only children using the PBO-PY LLIN benefited from the 285 protection as net usage and efficacy declined.<sup>35</sup> However in this trial, usage of PBO-PY LLIN during 286 the first two years of the study was much higher (from 79% to 54%) than reported in the present 287 study (74% to 30%) and could explain the difference of impact. 288

Pyriproxyfen-PY LLINs were designed to provide a community effect through sterilizing vectors as well as reducing the lifespan of female vectors after they were blood-fed<sup>36</sup> and survived exposure to the insecticide on the net. In the present trial, malaria prevalence was reduced in net users only at 12 months compared to the PY-only LLINs. There was no impact on non-net users living in the pyriproxyfen-PY LLINs arm compared to non-users in the PY-only LLIN arm except when coverage was greater than 40%. Pyriproxyfen-PY LLINs seem to have had limited or no impact on malaria indicators in other trial conducted in West Africa.<sup>29</sup>

296

It is worth noting in the present study that 36 months after distribution, individuals not using nets in the intervention study groups had lower odds of infection compared to those not using nets in the PYonly arm. This impact was likely associated with the distribution of new PBO-PY LLINs across all arms four months before the 36-month survey, which increased the usage of new nets and effective nets. In addition, PBO may enhance the efficacy of pyriproxyfen as it does for pyrethroid as these two insecticides may have similar mechanisms of resistance.<sup>37</sup>

Regardless of the impact of the net on non-net users, using any net was always more protective against malaria prevalence than not using one. This was observed for all net types including the PY-only LLIN. This result is consistent with other studies that reported higher malaria prevalence or incidence in non-net users compared to users sleeping under standard PY-only LLINs even in areas with pyrethroid resistance.<sup>38-42</sup>

This study has several limitations worth noting. The study was not designed for this secondary analysis and may have insufficient power to adequately assess separately the impact on users and non-users. Net usage was estimated on information provided by households' members which might not always be reliable. Finally, non-users were defined as children who did not sleep under any net the night before and might not capture occasional net usage during the week which also may influence the conclusions.

12

314 Regardless, this secondary analysis provides supplementary insight into the efficacy of these novel dual-active ingredient LLINs within a region characterized by moderate malaria transmission and 315 high resistance to pyrethroids. In settings with limited resources and the presence of insecticide 316 317 resistance, the deployment of an effective net, such as chlorfenapyr-PY, even at suboptimal coverage, could be considered as it would be more effective and even more cost-effective<sup>26</sup> than high coverage 318 of pyrethroid-only LLINs. This aligns with previous modelling work<sup>43</sup> which emphasized that a 319 massive reduction in mosquitoes would be more important than coverage alone. However, even the 320 most effective net in this study did not produce a sufficient reduction in mosquitoes to prevent users 321 of these nets from being exposed to high levels of malaria infection. A key message was that net users 322 were always better protected than non-users and therefore after providing the most effective nets, 323 national malaria control program could consider maximizing usage for better impact. Finally, as 324 observed by other studies44-49 pyrethroid-only nets still provided some protection in this area of 325 pyrethroid resistance. Non-users of nets in clusters where chlorfenapyr-pyrethroid nets were used 326 were better protected than non-users in clusters where pyrethroid only nets were used, but even the 327 more effective nets did not adequately control malaria and infection prevalence was still very high 328 even amongst users of these nets. New, more effective vector control tools are therefore urgently 329 330 needed to provide better protection against malaria than the protection provided by nets.

# 331 Conclusion

In areas where resistance to pyrethroids is prevalent in malaria vectors, chlorfenapyr-PY LLINs offer enhanced protection to individuals who use them as well as those who do not, even at lower coverage levels. This added protection for non-users is not seen with less effective nets containing PBO and pyriproxyfen unless the overall community usage exceeds 40%. Users were more protected than nonusers and emphasized the necessity to optimize net usage to benefit from their full potential. Nonetheless, in regions facing constrained financial resources and insecticide resistance, the distribution of the most effective net could be considered over the high-population coverage of

- 339 conventional nets. This strategic allocation would ensure maximal impact in the control of malaria
- despite limitations in resources and resistance challenges. 340
- 341 References
- 1. Cibulskis, R.E., et al., Malaria: Global progress 2000 - 2015 and future challenges. Infect Dis Poverty, 342 343 2016. 5(1): p. 61.
- WHO, World malaria report 2022. 2022. 344 2.
- 345 3. WHO, World malaria report 2019. 2019: Geneva.
- 346 WHO, World Malaria report 2023. 4.
- 347 5. Collins, W.E. and G.M. Jeffery, Plasmodium malariae: parasite and disease. Clin Microbiol Rev, 2007. 348 20(4): p. 579-92.
- Hawley, W.A., et al., Community-wide effects of permethrin-treated bed nets on child mortality and 349 6. 350 malaria morbidity in western Kenya. Am J Trop Med Hyg, 2003. 68(4 Suppl): p. 121-7.
- 351 7. Killeen, G.F., et al., Preventing childhood malaria in Africa by protecting adults from mosquitoes with 352 insecticide-treated nets. PLoS Med, 2007. 4(7): p. e229.
- 353 8. Hambisa, M.T., et al., Long lasting insecticidal net use and its associated factors in Limmu Seka 354 District, South West Ethiopia. BMC Public Health, 2018. 18(1): p. 124.
- 355 9. Eisele, T.P. and R.W. Steketee, African malaria control programs deliver ITNs and achieve what the 356 clinical trials predicted. PLoS Med, 2011. 8(9): p. e1001088.
- 357 10. Strode, C., et al., The impact of pyrethroid resistance on the efficacy of insecticide-treated bed nets against African anopheline mosquitoes: systematic review and meta-analysis. PLoS Med, 2014. 11(3): 358 359 p. e1001619.
- 360 11. Bayili, K., et al., Experimental hut evaluation of DawaPlus 3.0 LN and DawaPlus 4.0 LN treated with 361 deltamethrin and PBO against free-flying populations of Anopheles gambiae s.l. in Vallee du Kou, 362 Burkina Faso. PLoS One, 2019. 14(12): p. e0226191.
- 12. Menze, B.D., et al., An Experimental Hut Evaluation of PBO-Based and Pyrethroid-Only Nets against 363 the Malaria Vector Anopheles funestus Reveals a Loss of Bed Nets Efficacy Associated with GSTe2 364 365 Metabolic Resistance. Genes (Basel), 2020. 11(2).
- Chitnis, N., T. Smith, and R. Steketee, A mathematical model for the dynamics of malaria in 366 13. 367 mosquitoes feeding on a heterogeneous host population. J Biol Dyn, 2008. **2**(3): p. 259-85.
- Levitz, L., et al., Effect of individual and community-level bed net usage on malaria prevalence among 368 14. 369 under-fives in the Democratic Republic of Congo. Malar J, 2018. 17(1): p. 39.
- 370 Jo Lines, N.C.a.L.P., Systematic reviews, background papers and other unpublished evidence 15. 371 considered in the development of recommendations, in WHO Guidelines for malaria. 2022.
- 372 16. WHO, Implications of insecticide resistance for malaria vector control with long-lasting insecticidal 373 nets: trends in pyrethroid resistance during a WHO-coordinated multi-country prospective study. 374 Parasit Vectors, 2018. 11(1): p. 550.
- 375 17. Kim, S., et al., Using a human-centered design approach to determine consumer preferences for long-376 lasting insecticidal nets in Ghana. Glob Health Sci Pract, 2019. 7(2): p. 160-170.
- 377 Agossa, F.R., et al., Impact of insecticide resistance on the effectiveness of pyrethroid-based malaria 18. vectors control tools in Benin: decreased toxicity and repellent effect. PLoS One, 2015. 10(12): p. 378 379 e0145207.
- 380 Ranson, H., et al., Pyrethroid resistance in African anopheline mosquitoes: what are the implications 19. 381 for malaria control? Trends Parasitol, 2011. 27(2): p. 91-8.
- 382 20. Ranson, H. and N. Lissenden, Insecticide Resistance in African Anopheles Mosquitoes: A Worsening Situation that Needs Urgent Action to Maintain Malaria Control. Trends Parasitol, 2016. 32(3): p. 383 384 187-196.
- Protopopoff, N., et al., High level of resistance in the mosquito Anopheles gambiae to pyrethroid 385 21. 386 insecticides and reduced susceptibility to bendiocarb in north-western Tanzania. Malar J, 2013. 12: p. 387 149.

- 39224.Accrombessi, M., et al., Efficacy of pyriproxyfen-pyrethroid long-lasting insecticidal nets (LLINs) and393chlorfenapyr-pyrethroid LLINs compared with pyrethroid-only LLINs for malaria control in Benin: a394cluster-randomised, superiority trial. Lancet, 2023. **401**(10375): p. 435-446.
- Mosha, J.F., et al., Effectiveness of long-lasting insecticidal nets with pyriproxyfen-pyrethroid,
   *chlorfenapyr-pyrethroid, or piperonyl butoxide-pyrethroid versus pyrethroid only against malaria in Tanzania: final-year results of a four-arm, single-blind, cluster-randomised trial.* Lancet Infect Dis,
   2023.
- Mosha JF, K.M., Lukole E, Matowo NS, Pitt C, Messenger LA, Mallya E, Jumanne M, Aziz T, Kaaya R,
  Shirima BA, Isaya G, Taljaard M, Martin J, Hashim R, Thickstun C, Manjurano A, Kleinschmidt I, Mosha
  FW, Rowland M, Protopopoff N. , *Effectiveness and cost-effectiveness against malaria of three types*of dual-active-ingredient long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs in
  Tanzania: a four-arm, cluster-randomised trial. Lancet. 2022 Mar 26;399(10331):1227-1241. , 2022.
- Protopopoff, N., et al., *Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial.* Lancet, 2018. **391**(10130): p. 1577-1588.
- 40828.Staedke, S.G., et al., Effect of long-lasting insecticidal nets with and without piperonyl butoxide on409malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised trial embedded in a410national LLIN distribution campaign. Lancet, 2020. **395**(10232): p. 1292-1303.
- 41129.Tiono, A.B., et al., Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a412permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in413rural Burkina Faso: a cluster-randomised controlled trial. Lancet, 2018. **392**(10147): p. 569-580.
- 41430.Bonner, K., et al., Design, implementation and evaluation of a national campaign to distribute nine415million free LLINs to children under five years of age in Tanzania. Malar J, 2011. 10: p. 73.
- 41631.Jacklin F. Mosha, M.A.K., Louisa A. Messenger, Mark Rowland, Nancy Matowo, Catherine Pitt, Eliud417Lukole, Monica Taljaard, Charles Thickstun, Alphaxard Manjurano, Franklin W. Mosha, Immo418Kleinschmidt, Natacha Protopopoff, Protocol for a four parallel-arm, singleblind, cluster-randomised419trial to assess the effectiveness of three types of dual active ingredient treated nets compared to420pyrethroid-only long-lasting insecticidal nets to prevent malaria transmitted by pyrethroid421insecticideresistant vector mosquitoes in Tanzania. 2021.
- 422 32. Larsen, D.A., et al., *Community coverage with insecticide-treated mosquito nets and observed*423 *associations with all-cause child mortality and malaria parasite infections.* Am J Trop Med Hyg, 2014.
  424 91(5): p. 950-8.
- 425 33. Komazawa, O., et al., Are long-lasting insecticidal nets effective for preventing childhood deaths
  426 among non-net users? A community-based cohort study in western Kenya. PLoS One, 2012. 7(11): p.
  427 e49604.
- 428 34. Lindblade, K.A., et al., Sustainability of reductions in malaria transmission and infant mortality in
  429 western Kenya with use of insecticide-treated bednets: 4 to 6 years of follow-up. JAMA, 2004.
  430 291(21): p. 2571-80.
- 431 35. Protopopoff, N., et al., Effectiveness of piperonyl butoxide and pyrethroid-treated long-lasting
  432 insecticidal nets (LLINs) versus pyrethroid-only LLINs with and without indoor residual spray against
  433 malaria infection: third year results of a cluster, randomised controlled, two-by-two factorial design
  434 trial in Tanzania. Malar J, 2023. 22(1): p. 294.
- 43536.Kawada, H., et al., A small-scale field trial of pyriproxyfen-impregnated bed nets against pyrethroid-436resistant Anopheles gambiae s.s. in western Kenya. PLoS One, 2014. **9**(10): p. e111195.
- 437 37. Yunta, C., et al., *Pyriproxyfen is metabolized by P450s associated with pyrethroid resistance in An.*438 *gambiae.* Insect Biochem Mol Biol, 2016. **78**: p. 50-57.
- 439 38. Lindblade, K.A., et al., A cohort study of the effectiveness of insecticide-treated bed nets to prevent
  440 malaria in an area of moderate pyrethroid resistance, Malawi. Malar J, 2015. 14: p. 31.

It is made available under a CC-BY 4.0 International license .

Churcher, T.S., et al., *The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa.* Elife, 2016. 5.

Unwin, H.J.T., et al., *Quantifying the direct and indirect protection provided by insecticide treated bed nets against malaria*. Nat Commun, 2023. 14(1): p. 676.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.23.24301709; this version posted January 25, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

441 39. Kleinschmidt, I., et al., Implications of insecticide resistance for malaria vector control with long-442 lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study. 443 Lancet Infect Dis, 2018. 18(6): p. 640-649.

444 40. Ochomo, E., et al., Insecticide-Treated Nets and Protection against Insecticide-Resistant Malaria Vectors in Western Kenya. Emerg Infect Dis, 2017. 23(5): p. 758-764. 445

446 41. Bradley, J., et al., Insecticide-treated nets provide protection against malaria to children in an area of 447 insecticide resistance in Southern Benin. Malar J, 2017. 16(1): p. 225.

- 448 42. Tokponnon, F.T., et al., Impact of long-lasting, insecticidal nets on anaemia and prevalence of 449 Plasmodium falciparum among children under five years in areas with highly resistant malaria 450 vectors. Malar J, 2014. 13: p. 76.
- 451 43. Killeen, G.F., Control of malaria vectors and management of insecticide resistance through universal 452 coverage with next-generation insecticide-treated nets. Lancet, 2020. **395**(10233): p. 1394-1400.
- 453 44. Lengeler, C., Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev, 2004(2): p. CD000363. 454
- Pryce, J., M. Richardson, and C. Lengeler, Insecticide-treated nets for preventing malaria. Cochrane 455 45. Database Syst Rev, 2018. 11: p. CD000363. 456
- Gamble, C., J.P. Ekwaru, and F.O. ter Kuile, Insecticide-treated nets for preventing malaria in 457 46. 458 pregnancy. Cochrane Database Syst Rev, 2006. 2006(2): p. CD003755.
- 459 Barreaux, P., et al., Pyrethroid-treated bed nets impair blood feeding performance in insecticide 47. resistant mosquitoes. Sci Rep, 2023. 13(1): p. 10055. 460
- 461 48. Lindblade, K.A., et al., Impact of sustained use of insecticide-treated bednets on malaria vector species distribution and culicine mosquitoes. J Med Entomol, 2006. 43(2): p. 428-32. 462
- 463 49. Escamilla, V., et al., Effects of community-level bed net coverage on malaria morbidity in Lilongwe, Malawi. Malar J, 2017. 16(1): p. 142. 464

465

466

#### Acknowledgements 467

We thank colleagues and staff at Pan-African Malaria Vector Research Consortium (PAMVERC) in 468

Misungwi district, Mwanza region who were involved in the project. We acknowledge the assistance 469

provided by government leaders at the Misungwi District council (district, ward, village and hamlet 470

level). We thank Dr. Safari Kinung'hi (National Institute for Medical Research (NIMR)-Mwanza 471

Center) Former Misungwi District Commissioner) and Dr. Clement Morabu (Misungwi district 472

- medical officer) for their immense support for creating friendly atmosphere for running the project. 473
- Finally, we thank all the participating households for their cooperation. 474

475



